Related papers: Cross-Modal Knowledge Distillation for PET-Free Am…
Identifying amyloid-beta positive patients is crucial for determining eligibility for Alzheimer's disease (AD) clinical trials and new disease-modifying treatments, but currently requires PET or CSF sampling. Previous MRI-based deep…
Motivation: Alzheimer's Disease hallmarks include amyloid-beta deposits and brain atrophy, detectable via PET and MRI scans, respectively. PET is expensive, invasive and exposes patients to ionizing radiation. MRI is cheaper, non-invasive,…
Beta-amyloid positron emission tomography (A$\beta$-PET) imaging has become a critical tool in Alzheimer's disease (AD) research and diagnosis, providing insights into the pathological accumulation of amyloid plaques, one of the hallmarks…
Synthesizing amyloid PET scans from the more widely available and accessible structural MRI modality offers a promising, cost-effective approach for large-scale Alzheimer's Disease (AD) screening. This is motivated by evidence that, while…
Amyloid-$\beta$ (A$\beta$) plaques in conjunction with hyperphosphorylated tau proteins in the form of neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease. It is well-known that the identification of…
In this work, an image translation model is implemented to produce synthetic amyloid-beta PET images from structural MRI that are quantitatively accurate. Image pairs of amyloid-beta PET and structural MRI were used to train the model. We…
Background: Alzheimer's disease (AD) diagnosis heavily relies on amyloid-beta positron emission tomography (Abeta-PET), which is limited by high cost and limited accessibility. This study explores whether Abeta-PET spatial patterns can be…
Mild cognitive impairment (MCI) conversion prediction, i.e., identifying MCI patients of high risks converting to Alzheimer's disease (AD), is essential for preventing or slowing the progression of AD. Although previous studies have shown…
This study proposes a deep learning-based framework for automated segmentation of brain regions and classification of amyloid positivity using positron emission tomography (PET) images alone, without the need for structural MRI or CT. A 3D…
The integration of multimodal medical imaging can provide complementary and comprehensive information for the diagnosis of Alzheimer's disease (AD). However, in clinical practice, since positron emission tomography (PET) is often missing,…
Alzheimer's disease (AD) is the most prevalent form of dementia, and its early diagnosis is essential for slowing disease progression. Recent studies on multimodal neuroimaging fusion using MRI and PET have achieved promising results by…
Recent studies suggest that combined analysis of Magnetic resonance imaging~(MRI) that measures brain atrophy and positron emission tomography~(PET) that quantifies hypo-metabolism provides improved accuracy in diagnosing Alzheimer's…
Structural MRI-to-amyloid PET synthesis has been proposed as a non-invasive alternative for amyloid assessment in Alzheimer's disease (AD). However, reported performance of identical models varies widely across studies, and increasingly…
The biological definition of Alzheimer's disease (AD) relies on multi-modal neuroimaging, yet the clinical utility of positron emission tomography (PET) is limited by cost and radiation exposure, hindering early screening at preclinical or…
The early detection of Alzheimer's Disease is imperative to ensure early treatment and improve patient outcomes. There has consequently been extenstive research into detecting AD and its intermediate phase, mild cognitive impairment (MCI).…
[18F]-florbetaben positron emission tomography (PET) imaging is an established marker of {\ss}-Amyloid (A{\ss}) that is being increasingly used to assess A{\ss} deposition in AD. This study presents a novel, explainable machine…
Positron emission tomography (PET) is a well-established functional imaging technique for diagnosing brain disorders. However, PET's high costs and radiation exposure limit its widespread use. In contrast, magnetic resonance imaging (MRI)…
For effective treatment of Alzheimer disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline. Herein, we developed a novel framework based on a deep convolutional neural network which can…
Diagnosing dementia, particularly for Alzheimer's Disease (AD) and frontotemporal dementia (FTD), is complex due to overlapping symptoms. While magnetic resonance imaging (MRI) and positron emission tomography (PET) data are critical for…
Alzheimer's disease is a progressive neurodegenerative disorder in which mild cognitive impairment (MCI) marks a critical transition between aging and dementia. Neuroimaging modalities, such as structural MRI, provide biomarkers of this…